Krystal Biotech, Inc. $KRYS Stock Position Increased by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC

Key Points

• UBS Asset Management Americas LLC significantly increased its stake in Krystal Biotech, Inc. by 173.8%, acquiring 365,304 shares to own a total of 575,506 shares valued at $103.76 million.
• Several other institutional investors also boosted their holdings in Krystal Biotech, leading to a total institutional ownership of 86.29% of the company's stock.
• Krystal Biotech has posted strong quarterly earnings with an EPS of $1.29, exceeding analyst expectations, and has been assigned a "Moderate Buy" rating by investment analysts with a consensus price target of $209.00.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 173.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 575,506 shares of the company's stock after acquiring an additional 365,304 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 1.99% of Krystal Biotech worth $103,764,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Brooklyn Investment Group grew its holdings in Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after purchasing an additional 105 shares in the last quarter. Twin Tree Management LP acquired a new stake in Krystal Biotech during the 1st quarter valued at $29,000. Fifth Third Bancorp grew its holdings in Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after purchasing an additional 105 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in Krystal Biotech by 128.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company's stock valued at $58,000 after purchasing an additional 177 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Krystal Biotech during the 1st quarter valued at $74,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $150.30, for a total value of $2,019,280.50. Following the completion of the transaction, the insider directly owned 1,443,276 shares of the company's stock, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 49,800 shares of company stock valued at $7,487,943. Insiders own 13.70% of the company's stock.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS traded up $6.56 during midday trading on Thursday, hitting $160.61. The company's stock had a trading volume of 364,668 shares, compared to its average volume of 299,087. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $207.84. The firm's fifty day moving average price is $147.67 and its 200-day moving average price is $152.22. The firm has a market cap of $4.65 billion, a P/E ratio of 32.64 and a beta of 0.66.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, beating the consensus estimate of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The business had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. As a group, research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on KRYS shares. HC Wainwright reaffirmed a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a report on Monday. Bank of America lowered their price target on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Citigroup reaffirmed a "neutral" rating and set a $166.00 price target (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Finally, Chardan Capital decreased their price objective on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a report on Friday, August 22nd. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $209.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).